• Hypertrophic Cardiomyopathy (HCM)
  • Eyecare
  • Urothelial Carcinoma
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

MHE State of the Industry survey: COVID-19 ranks No.1

MHE PublicationMHE December 2020
Volume 30
Issue 12

Respondents ranked the importance of healthcare issues.

MHE conducted our annual State of the Industry reader survey in October and November. Respondents were asked to rank the importance of healthcare issues and, no surprise, 71% of the rankings of COVID-19 by the respondents rated it as the number one healthcare issue. High drug prices were ranked as second most important healthcare issue by 29% of the respondents.

We also asked respondents to rank their level of agreement with a variety of statements about U.S. healthcare. Agreement was strongest (56%) with the statement, “The increasing enrollment in Medicare Advantage is a positive development,” and the strongest disagreement (62%) was with the statement, “Drug prices are high, but high prices mean investment in research and development.”

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.